Q-omics provides the consensus-scored MTIF3 profile across patient tissues and cancer cell-line models. MTIF3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MTIF3 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, MTIF3 RNA expression shows 19,112 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KICH, and UVM as cancer lineages where MTIF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTIF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTIF3 survival associations across molecular data types. MTIF3 RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTIF3 RNA expression–survival associations across cancer types. High MTIF3 expression shows unfavorable associations in UVM, READ and KICH, but favorable associations in MESO, BLCA and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MTIF3 RNA expression.
This table summarizes MTIF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 8. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MTIF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTIF3 shows lower tumor expression in KICH, KIRP, THCA and UCEC and higher tumor expression in LIHC and KIRC. The KICH box plot shows higher MTIF3 RNA expression in normal versus tumor tissue (log2 FC = −1.014, t-test p < 0.001).
This table shows molecular features associated with MTIF3 in patient tissues and cancer cell lines. In patient samples, MTIF3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MTIF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
